Evidence map›Paper›PMID 35641234›Full record

ArticleBritish medical bulletin2022

Antiresorptive treatments for corticosteroid-induced osteoporosis: a Bayesian network meta-analysis.

Filippo Migliorini, Giorgia Colarossi, Jörg Eschweiler, Francesco Oliva, Arne Driessen, Nicola Maffulli

Abstract readNetwork Meta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Article in British medical bulletin, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 101 papers, 18 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
101citing papers in PubMed, 18 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

101 citing papers in PubMed, 18 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Guideline
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Pooled it
  17. Pooled it
  18. Pooled it
  19. Trial
  20. Trial

41 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Filippo MiglioriniDepartment of Orthopaedic and Trauma Surgery, University Clinic Aachen, RWTH Aachen University Clinic, Aachen 52074, Germany.
Giorgia ColarossiDepartment of Orthopaedic and Trauma Surgery, University Clinic Aachen, RWTH Aachen University Clinic, Aachen 52074, Germany.
Jörg EschweilerDepartment of Orthopaedic and Trauma Surgery, University Clinic Aachen, RWTH Aachen University Clinic, Aachen 52074, Germany.
Francesco OlivaDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi (SA), Italy.
Arne DriessenDepartment of Orthopaedic and Trauma Surgery, University Clinic Aachen, RWTH Aachen University Clinic, Aachen 52074, Germany.
Nicola MaffulliDepartment of Medicine, Surgery and Dentistry, University of Salerno, Via S. Allende, 84081 Baronissi (SA), Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionCorticosteroid-induced osteoporosis (CIO) is the most common type of secondary osteoporosis, leading to fractures, and increased morbidity and mortality. SOURCE OF DATA: Pubmed, EMBASE, Scopus and Google Scholar databases. AREAS OF AGREEMENT: Prolonged glucocorticoids administration leads to secondary osteoporosis. AREAS OF CONTROVERSY: The optimal management for CIO is controversial. GROWING POINTS: The present study compared bone mineral density, fractures and adverse events in patients undergoing treatment with risedronate, alendronate, zoledronate, denosumab or etidronate for CIO. AREAS TIMELY FOR DEVELOPING RESEARCH: For selected patients with CIO, alendronate performed better overall. These results must be interpreted within the limitations of the present study. LEVEL OF EVIDENCE: I, Bayesian network meta-analysis of randomized clinical trials.

Indexed as

Adrenal Cortex HormonesOsteoporosisAlendronateBayes TheoremBone Density Conservation AgentsDenosumabEtidronic AcidGlucocorticoidsHumansRisedronic AcidZoledronic AcidAdrenal Cortex HormonesAlendronateBone Density Conservation AgentsDenosumabEtidronic AcidGlucocorticoidsRisedronic AcidZoledronic AcidalendronateBMDcorticosteroiddrugsfractureosteoporosis

Identifiers

PMID35641234
PMCPMC9494254

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.